Jiangsu Lianhuan Pharmaceutical Co (600513) Fair Value & Analysis

Healthcare · CN · Market cap 5.2B CNY

Below-average quality, and screening another 68% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case (¥7.80). The favourable scenario is already priced in.
• Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts.
• A fairly wide model range (¥3.90 to ¥7.80) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 8, 2026.

How to read this chart

60‑month range ¥7.14 – ¥30.75 · fair‑value band ¥3.90 – ¥7.80 · the ¥18.07 price screens above the ¥5.85 fair value. Dashed = 300-day average. As of Aug 8, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Jiangsu Lianhuan Pharmaceutical Co (600513) currently trades at ¥18.07, while our model-based Fair Value estimate is ¥5.85, implying the stock looks roughly 67.6% overvalued today. The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).

Over the trailing twelve months, Jiangsu Lianhuan Pharmaceutical Co generated revenue of 2.9B CNY at a net margin of -4.0%. Revenue grew 29.1% year over year. It earns a return on equity of -6.0%. Net debt stands at 556M CNY. Fundamentals as of Aug 8, 2026

Our scenario range runs from ¥3.90 (bear case) to ¥7.80 (bull case); at ¥18.07, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 44% below its 52-week high and 100% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -68%, 600513 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Multiples (¥6.48) versus Dividend Discount (¥2.68). Highest evidence: Residual Income (76).

Key figures & financial health

Quality Score breakdown

About the company

Jiangsu Lianhuan Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells pharmaceuticals, preparations, and active pharmaceutical ingredients (API) products in China and internationally.

Full company description

Jiangsu Lianhuan Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells pharmaceuticals, preparations, and active pharmaceutical ingredients (API) products in China and internationally. The company offers clopidogrel bisulfate tablets, doxycycline hydrochloride, azithromycin, milrinone, dapoxetine hydrochloride, tadalafil, and betasine besylate tablets, as well as aprilite, danazol suppositories, and terfenadine tablets. It also provides urinary system drugs, including eprepitant tablets, terazosin tablets, and drotaverine hydrochloride injections; antihistamines comprising ebastine, terfenadine, and cetirizine hydrochloride tablets; cardiovascular drugs that include felodipine, simvastatin, and amlodipine maleate tablets; steroid hormones, which consist of prazosinone sulfate sodium for injection and danazol capsules; and antibiotics, such as oxithromycin capsules. In addition, the company offers API products, such as hydrocortisone, hydrocortisone acetate, levonorgestrel, dexamethasone sodium phosphate, dexamethasone acetate, tazarotene, saxagliptin monohydrate, sacubitril valsartan sodium, phentolamine mesylate, terfenadine, aminomethylbenzoic acid, drotaverine hydrochloride, felodipine, ebastine, lumbrokinase, chloramphenicol, balofoxacin, fludrocortisone acetate, relugolix, hydrocortisone valerate, and bilastine. Further, it engages in the wholesale of chemical raw materials and pharmaceuticals, as well as the sale of medical equipment and electronic products. The company exports its products. Jiangsu Lianhuan Pharmaceutical Co., Ltd. was founded in 1999 and is based in Yangzhou, China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2020 – FY2024 · reported fiscal years

Jiangsu Lianhuan Pharmaceutical Co reported revenue of ¥2.2B in FY2024 versus ¥1.4B in FY2020, a compound +11.7%/yr. Reported net income was ¥84.2M in FY2024, compounding −4.9%/yr from FY2020.

600513 screens 68% overvalued. Compare with Sun Pharmaceutical Industries Limited →

Peer Group

Drug Manufacturers - Specialty & Generic · 626 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 8, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.